Graded by the fourth independent, annual benchmark evaluation of the Spanish healthcare sector, Monitor de Reputación Sanitaria (MRS), issued by the Business Monitor of Corporate Reputation (MERCO) today, the Medical Oncology Department of the Vall d’Hebron University Hospital (HUVH), championed by Josep Tabernero, Director of VHIO and President-Elect of the European Society for Medical Oncology (ESMO), ranks first among clinical services in medical oncology with the very best reputation at national level for a fourth year running.

In addition, for a consecutive year, HUVH, located within the Vall d’Hebron Barcelona Hospital Campus, earns 5th place in the ranking of public hospitals throughout Spain and also secures top 5 slot listings for the following additional specialties: cardiology, pneumology, neurology, gynecology and obstetrics, general surgery, hematology, pediatrics, internal medicine, oral & maxillofacial surgery, orthopedic surgery & traumatology, and hospital pharmacy.

In recognition of these achievements, we at the Vall d’Hebron Institute of Oncology (VHIO), would like to congratulate both the HUVH and Josep Tabernero, as well as recognize the outstanding dedication and commitment of his exceptional team of oncology professionals — the driving force behind Spain’s leading Medical Oncology Service.

Not only do we thoroughly applaud the tremendous efforts of the entire Department, we also take the opportunity to recognize those medical oncologists who, in addition to their duties as leading physicians, also carry out clinical research of excellence at VHIO.

Marking an exceptional month of recognition for VHIO and the Vall d’Hebron University Hospital’s Medical Oncology Department

Within the space of a month, thanks to our Institute’s purely multidisciplinary teams, incorporating VHIO’s talented cancer researchers, top drawer clinical investigators, and leading physicians at HUVH’s Medical Oncology Department, that our collective efforts have also been recognized by the European Alliance for Personalised Medicine (EAPM) for best integrating personalised medicine in oncology – announced and awarded to VHIO last night, and Gaceta Médica‘s Best-in-Class Prize for R&D in oncology in recognition of VHIO’s contribution to the Spanish National Health System.

For more information on both these achievements please click on the respective VHIO news below:

VHIO “HI-5’D” by the European Alliance for Personalised Medicine (EAPM) for best integrating personalized medicine in oncology

VHIO picks up Best-in-Class Prize awarded by Gaceta Médica

###